Second drug gets UK early access scheme nod
This article was originally published in SRA
Executive Summary
In what appears to be just the second such decision by the UK regulator, the MHRA, Bristol-Myers Squibb's advanced melanoma product Opdivo (nivolumab) has been given the go-ahead to enter the early access to medicines scheme (EAMS), meaning it can be made available to patients in the UK in advance of its eventual EU approval1.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.